Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
FeaturedThe Kerala High Court is concluding the final hearing on the Ribociclib litigation, a pivotal case in pharmaceutical patent law. The outcome may have significant implications for access to medicines in India.
FeaturedIn Intra Cellular Therapies v. Controller of Patents, the Delhi High Court revisits key elements of pharmaceutical patent law, focusing on disclosure and efficacy standards.
FeaturedThe Delhi High Court's ruling in Intra Cellular Therapies v. Controller of Patents examines key issues in pharmaceutical patent law, including disclosure standards and the efficacy threshold under Section 3(d). The decision influences future patent applications significantly.
A recent analysis reflects on the limitations of India’s patent law provisions relying on Sections 92 and 100, highlighting the ongoing Ribociclib litigation as a critical case study. The emphasis is laid on the infrastructure challenges rather than merely legal impediments in improving access to patented medications.
Khaitan & Co has facilitated a Composite Scheme of Arrangement for the amalgamation of Woodlands Multispeciality Hospital and RPSG Ventures Limited.
The Kerala High Court has mandated that practitioners of electro-homeopathy must register under state laws, asserting that the practice cannot be viewed as unregulated.
The CGPDTM has issued new draft guidelines aimed at improving the examination process of pharmaceutical and biotechnology patent applications.
The Controller General of Patents has invited comments on new draft patent application guidelines. These are aimed at improving patenting procedures for pharmaceutical and biotech inventions.
The Central Drugs Standard Control Organization seeks feedback on brand name extensions by pharmaceutical companies. This marks a notable regulatory shift in oversight of pharmaceutical branding.
This article provides an overview of the regulations surrounding drug licensing in India, a critical component for pharmaceutical operations. It focuses on the necessary steps and legal requirements for obtaining a Drug License.
The abandonment of Mavyret's patent does not open the market for Hepatitis C generics in India. Despite the government's efforts towards eliminating Hepatitis C by 2030, AbbVie’s Mavyret remains a key player in the treatment landscape.
The Central Drugs Standard Control Organization (CDSCO) is inviting stakeholder comments on its policies regarding brand name extensions in the pharmaceutical sector. This move could lead to crucial changes in the practice of branding in the industry.